Search clinical trials for: ELC200 (carbidopa+levodopa+entacapone)

Total 184 results

IRCCS San Raffaele Roma
SynAgile Corporation

Completed

Intermittent Oral Administration vs. Semi-continuous Intra-oral Administration of Levodopa/Carbidopa in Fluctuating Parkinsonian Patients (LDCD-001)

Parkinson Disease

Italy
Kevin J. Black, MD
The Michael J. Fox Foundation for Parkinson's Research

Completed

Measuring Parkinson's Disease Progression (MPDP)

Parkinson's Disease

United States
UCB Pharma

Completed

A Multicenter, Open-label Trial to Assess Subject Preference of PARCOPA, Carbidopa/Levodopa Orally Disintegrating Tablets, Compared to Conventional Carbidopa/Levodopa Tablets in Subjects With Stable Parkinson's Disease

Parkinson's Disease

United States
Impel Pharmaceuticals

Completed

Therapeutic Potential for Intranasal Levodopa in Parkinson's Disease -Off Reversal (THOR201)

Parkinson's Disease

Australia
Depomed

Completed

Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations

Parkinson's Disease | Motor Fluctuations

United States
Acorda Therapeutics

Completed

Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder)

Parkinson's Disease

United States
UCB Pharma

Completed

A Single Center, Randomized, Double-blind, Crossover Pilot Trial Comparing the Onset of Action of Parcopa™ With Sinemet® in Subjects With Stable Parkinson's Disease

Parkinson's Disease

United States
LobSor Pharmaceuticals AB
TFS Trial Form Support

Completed

A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients

Parkinson's Disease

Sweden
Maastricht University Medical Center

Completed

Dopaminergic Modulation of Cognition and Psychomotor Function

Dopamine Activity | Episodic Memory Consolidation | Response Preparation

Netherlands
Impax Laboratories, LLC
Michael J. Fox Foundation for Parkinson's Research

Completed

Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety Study

Parkinson's Disease

United States
University of California, Los Angeles

Completed

Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke

Stroke

United States
Orion Corporation, Orion Pharma

Completed

Dose-finding Pharmacokinetic Study in Healthy Males (COMDOS1)

Healthy Volunteers

Germany
Bial - Portela C S.A.

Completed

Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)

Parkinson's Disease

Portugal
Poitiers University Hospital

Completed

Clinical and Economic Impact of Duodopa: Long-term Effectiveness Study in Advanced Parkinson's Disease Patients

Parkinson's Disease

France
Milton S. Hershey Medical Center
Pfizer

Completed

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

Parkinson Disease

United States
Aarhus University Hospital
University of Copenhagen

Unknown

Common Noradrenergic Mechanisms in Parkinson´s Disease and L-DOPA Induced Dyskinesia (NORAPARK)

Parkinson´s Disease

Denmark
Nordic Life Science Pipeline Inc.
United States Department of Defense

Completed

Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury

Spinal Cord Injury

Canada
Northwestern University
National Institutes of Health (NIH); Shirley Ryan AbilityLab

Recruiting

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

Back Pain | Chronic Pain | Chronic Low-back Pain | Opioid Dependence | Opioid Use | Pain, Chronic | Back Injuries | Opioid-use Disorder | Pain, Back | Narcotic Use | Pain;Back Low;Chronic

United States
Merck Sharp & Dohme LLC
Oregon Health and Science University

Completed

Acute Effects of Preladenant (SCH 420814) on Dyskinesia and Parkinsonism in Levodopa Treated Participants (P05550)

Parkinson Disease
The University of Texas Health Science Center,...
National Institute on Drug Abuse (NIDA)

Completed

Medications for Stopping Cocaine Dependence and Preventing Relapse

Cocaine-Related Disorders | Cocaine Abuse

United States
Impax Laboratories, LLC

Completed

A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's Disease

Advanced Parkinson's Disease

United States
The University of Texas Health Science Center,...
National Institute on Drug Abuse (NIDA); University of Texas

Completed

Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence

Cocaine-Related Disorders | Cocaine Abuse

United States
Vastra Gotaland Region
The Swedish Research Council; Göteborg University; Dizlin Medical Design AB

Completed

Study Comparing Intravenous and Subcutaneous Infudopa With Intestinal Duodopa in Patients With Parkinson's Disease (IPO-001)

Parkinson Disease

Sweden
National Institute of Neurological Disorders and...

Terminated

Augmenting Effects of L-DOPS With Carbidopa and Entacapone

Parkinson Disease | Autonomic Nervous System Diseases | Multiple System Atrophy

United States
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa

Parkinson's Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetics of Rising Single-doses of BIA 6-512 and Their Effect on the Levodopa Pharmacokinetics

Parkinson Disease

Portugal
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
Bial - Portela C S.A.

Completed

Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients. (BIPARKII)

Parkinson's Disease

Portugal
Impax Laboratories, LLC

Completed

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

Parkinson's Disease (Disorder)

United States, Czechia, France, Italy, Spain, Germany, Poland, United Kingdom
NeuroDerm Ltd.

Active, not recruiting

Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)

Parkinson's Disease

United States, Israel, Spain, France, Russian Federation, Austria, Italy, Belgium, Czechia, Hungary, Netherlands, Poland, Portugal, Slovakia, Ukraine, United Kingdom
Bial - Portela C S.A.

Completed

Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa

Parkinson's Disease (PD)

Canada
City of Hope Medical Center
Addario Lung Cancer Medical Institute

Withdrawn

ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung Cancer

Extensive Stage Small Cell Lung Carcinoma

United States
Hospital de Granollers

Completed

Effect of Serotonin and Levodopa in Ischemic Stroke (SELEIS)

Stroke

Spain
Vanderbilt University

Completed

Treatment of Orthostatic Hypotension in Autonomic Failure

Orthostatic Hypotension | Autonomic Failure

United States

Search clinical trials for: ELC200 (carbidopa+levodopa+entacapone)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations